Eric R. Siegel

High Impact

Research Associate

University of Arkansas for Medical Sciences

postdoc

50 h-index 414 pubs 9,611 cited

Research Areas

Cancer Treatment and Pharmacology Cancer Immunotherapy and Biomarkers Immune Response and Inflammation Multiple Myeloma Research and Treatments Cancer-related molecular mechanisms research Diet and metabolism studies Immune Cell Function and Interaction CAR-T cell therapy research

Links

ORCID Google Scholar Research Group

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Eric R. Siegel's research centers on the investigation of cancer, with a particular focus on endometrial, multiple myeloma, and colorectal cancers. His work examines the efficacy of various therapeutic agents, including pembrolizumab, sacituzumab govitecan-hziy, and bispecific CAR-T cells, in treating these malignancies. Siegel has published findings related to the immune microenvironment in multiple myeloma and its precursor stages, as well as the impact of dietary interventions on immune responses in colorectal cancer models.

His research also delves into the molecular mechanisms underlying cancer development and progression. This includes investigating the role of specific genes, such as NEK2, in suppressing T-cell immunity in multiple myeloma and understanding the immune microenvironment alterations in different stages of the disease. Siegel has also explored the tolerability of treatments like trastuzumab in uterine serous carcinomas.

With a substantial publication record (414 publications) and a high citation count (9,611), Siegel is recognized as a highly cited researcher. He leads a research group and collaborates with several colleagues at the University of Arkansas for Medical Sciences, including Simon C. Mears, Sharmilan Thanendrarajan, John D. Shaughnessy Jr., and Maurizio Zangari, with whom he has co-authored multiple publications.

Metrics

h-index: 50
Publications: 414
Citations: 9,611

Selected Publications

Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025) DOI
A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses (2025) DOI
Does Patient Health Literacy Affect Patient Reported Outcome Measure Completion Method in Orthopaedic Patients? (2025) DOI
A customized bed based stand alone array of optically pumped magnetometers for fetal magnetocardiography measurements (2025) DOI
Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma (2025) DOI
N-acetylcysteine (NAC) supplementation improves dyspnea and may normalize von Willebrand plasma levels in gynecologic patients with Post-Acute-COVID-Sequela (PASC)/Long COVID (2025) DOI
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024) DOI
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024) DOI
Does Body Mass Index Affect the Success of Two-Stage Management of Periprosthetic Joint Infection? (2024) DOI
Younger and rural children are more likely to be hospitalized for SARS-CoV-2 infections (2024) DOI
Pediatric Off-Road Vehicle Injuries (2024) DOI
Correlating maternal and cord-blood inflammatory markers and BDNF with human fetal brain activity recorded by magnetoencephalography: An exploratory study (2024) DOI
Fetal magnetocardiographic recordings with a prototype bed-based array system of optically-pumped magnetometers (2024) DOI
Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix (2024) DOI
Successful Transition to Same Calendar Day Discharge in Total Joint Arthroplasty at an Academic Center (2024) DOI